Loading…
JAMP-CARVEDILOL is a brand name for Carvedilol, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS ............................................................................................. 4 WARNINGS AND PRECAUTIONS............................................................................. 4 ADVERSE…
Verbatim from this product's HC label. Tap a section to expand.
g. severe Alzheimer's, alcoholism, drug abuse), unless closely supervised by an appropriate caregiver hypersensitivity to carvedilol or any component of carvedilol tablets. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING.
WARNINGS AND PRECAUTIONS Warnings and precautions are listed in alphabetical order. General Abrupt Cessation of Therapy In patients with heart failure treated chronically with carvedilol, abrupt cessation of therapy may lead to deterioration.
Therefore discontinuation of carvedilol should be done gradually, if possible. Patients with ischemic heart disease should be warned against abrupt discontinuation of beta- adrenergic blocking agents. There have been reports of severe exacerbation of angina, and of myocardial infarction or ventricular arrhythmias occurring in patients with angina pectoris, following abrupt discontinuation of beta-blocker therapy.
The last two complications may occur with or without preceding exacerbation of angina pectoris. Therefore, when discontinuing carvedilol in patients with angina pectoris, the dosage should be gradually reduced over a period of about 2 weeks and the patient should be carefully observed.
The same frequency of administration should be maintained. In situations of greater urgency, carvedilol therapy should be discontinued stepwise and under conditions of closer observation. If JAMP-Carvedilol Product Monograph Page 5 of 38 angina markedly worsens or acute coronary insufficiency develops, it is recommended that treatment with the drug be re-instituted promptly, at least temporarily.
Oculomucocutaneous Syndrome Various skin rashes and conjunctival xerosis have been reported with beta-blockers. A severe syndrome (oculomucocutaneous syndrome) whose signs include conjunctivitis sicca and psoriasiform rashes, otitis, and sclerosing serositis has occurred with the chronic use of one beta- adrenergic blocking agent (practolol).
This syndrome has not been observed in association with carvedilol or any other such agent. However, physicians should be alert to the possibility of such reactions and should discontinue treatment in the event that they occur. Cardiovascular Cardiac Failure Worsening cardiac failure may occur during initiation and up-titration of carvedilol.
Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and inhibition with beta-blockade may further depress myocardial contractility. Cardiac failure should be controlled for at least 4 weeks before carvedilol treatment is initiated.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Carvedilol in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
In clinical trials of mild to moderate heart failure, patients were required to be on stable doses of diuretics and ACE inhibitors (if tolerated) prior to the initiation of carvedilol. Despite these steps to ensure stability, a small number of patients with mild to moderate heart failure developed worsening heart failure.
d. 0% of patients developed worsening congestive heart failure. d. 1% of placebo patients. 8%). When treatment was maintained beyond 3 months, worsening heart failure was reported less frequently in patients treated with carvedilol than with placebo.
Worsening heart failure observed during long-term therapy is more likely to be related to the patients’ underlying disease than to treatment with carvedilol. Administration of carvedilol to patients with controlled heart failure must be carried out under careful supervision.
If symptoms occur, diuretics should be increased and the carvedilol dose not advanced or even lowered until clinical stability resumes (see DOSAGE AND ADMINISTRATION). However, it may be necessary to discontinue carvedilol. Such episodes may not preclude subsequent successful titration of the drug or a favorable response to carvedilol.
Hypotension Hypotension and postural hypotension in congestive heart failure patients occurred with a higher incidence in carvedilol-treated than in placebo-treated patients (see ADVERSE REACTIONS). The risk of these events was highest during initiation of therapy and during the first 30 days of JAMP-Carvedilol Product Monograph Page 6 of 38 dosing corresponding to the up-titration period.
Therefore, it is of critical importance that the dosing recommendation be followed (see DOSAGE AND ADMINISTRATION). Peripheral Vascular Disease Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.
Caution should be exercised in such individuals. Primary Regurgitative Valvular Heart Disease Carvedilol should be used with caution in patients with primary regurgitative valvular disease as experience in this patient population is limited.
Prinzmetal’s Angina Beta-blocking agents may provoke chest pain in patients with Prinzmetal’s angina. There has been no clinical experience with carvedilol in these patients. Caution should be taken in […]